Olema Pharmaceuticals, Inc.

OLMA · Healthcare · Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of th…

Olema Pharmaceuticals, Inc. (OLMA), in the Healthcare sector, has 9 disclosed filings on Paydirt over the trailing twelve months from 6 corporate insiders: 0 purchases and 9 sales. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Jul 24 and filed Jul 27. The most active filer was G. Walmsley Graham with 3 filings.

Add to watchlist

Filings, ttm

0 buys · 9 sells

Traders, ttm

6 insiders

Volume, ttmiDollar value disclosed in the window

$24.6M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

Jul 24

Filed Jul 27

ADViAverage daily dollar volume

$15.8M

market data

Share price · 12M

$10.72 (+28.7%)

Adjusted for splits and dividends.

Volume by month

Buys $6.5M Sells $53.3M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed

GG G. Walmsley Graham Director 3 filings CH Cyrus Harmon Director 3 filings DM David C. Myles CH. DISCOV. & NON-CLIN DEV OFF 3 filings SK Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. 2 filings NZ Naseem Zojwalla Chief Medical Officer 2 filings BL Bain Capital Life Sciences Investors, LLC 10% owner 1 filing SB Sean Bohen PRESIDENT AND CEO 1 filing IC

Ian T Clark Director 1 filing

Recent filings

Cyrus HarmonSALE Director $291K
25,000 sh across 2 lots
Exec Jul 23
Filed Jul 27 · 7:30 PM ET Shawnte MitchellSALE CHIEF LEGAL OFFICER $946K
39,767 sh across 2 lots
Exec Mar 3
Filed Mar 5 · 5:30 PM ET Cyrus HarmonSALE Director $269K
10,000 sh × $26.88
Exec Jan 20
Filed Jan 21 · 5:30 PM ET Cyrus HarmonSALE Director $102K
3,489 sh × $29.12
Exec Jan 14
Filed Jan 16 · 5:30 PM ET Shane William Charles KovacsSALE CH. OPERATING & FINANCIAL OFF. $3.0M
103,822 sh across 2 lots
Exec Jan 13
Filed Jan 15 · 5:30 PM ET David C. MylesSALE CH. DISCOV. & NON-CLIN DEV OFF $3.1M
109,800 sh across 4 lots
Exec Jan 12
Filed Jan 14 · 5:30 PM ET Naseem ZojwallaSALE Chief Medical Officer $7.5M
269,509 sh across 4 lots
Exec Dec 19 2025
Filed Dec 23 2025 · 5:30 PM ET David C. MylesSALE CH. DISCOV. & NON-CLIN DEV OFF $1.5M
49,775 sh across 2 lots
Exec Dec 19 2025
Filed Dec 23 2025 · 5:30 PM ET Ian T ClarkSALE Director $7.9M
264,800 sh across 3 lots
Exec Dec 19 2025
Filed Dec 23 2025 · 5:30 PM ET Bain Capital Life Sciences Investors, LLCPURCHASE 10% owner $1.7M
300,000 sh × $5.76
Exec Jan 8 2025
Filed Jan 13 2025 · 5:30 PM ET † G. Walmsley GrahamSALE Director $4.7M
700,761 sh × $6.75
Exec Dec 13 2024
Filed Dec 18 2024 · 5:30 PM ET † G. Walmsley GrahamPURCHASE Director $4.7M
700,761 sh × $6.75
Exec Dec 13 2024
Filed Dec 18 2024 · 5:30 PM ET † G. Walmsley GrahamSALE Director $4.7M
700,761 sh × $6.75
Exec Dec 17 2024
Filed Dec 17 2024 · 5:30 PM ET Sean BohenSALE PRESIDENT AND CEO $974K
108,235 sh across 2 lots
Exec Dec 10 2024
Filed Dec 11 2024 · 5:30 PM ET Shane William Charles KovacsSALE CH. OPERATING & FINANCIAL OFF. $313K
34,753 sh across 2 lots
Exec Dec 10 2024
Filed Dec 11 2024 · 5:30 PM ET Naseem ZojwallaSALE CHIEF MEDICAL OFFICER $247K
27,485 sh across 2 lots
Exec Dec 10 2024
Filed Dec 11 2024 · 5:30 PM ET David C. MylesSALE CH. DISCOV. & NON-CLIN DEV OFF $232K
25,766 sh across 2 lots
Exec Dec 10 2024
Filed Dec 11 2024 · 5:30 PM ET G. Walmsley GrahamSALE Director $17.4M
1,175,000 sh across 2 lots
Exec Jun 4 2024
Filed Nov 26 2024 · 5:30 PM ET †